Cai Lin

40,.: (ASP). 、. 、..... 20, 、 ( 1.1,,, (Tofacitinib),TYK2, ),,,, 2,. 100, 8, 4,,985.: 1.Cai L, Gu J, Zheng J, Zheng M, Wang G, Xi LY, Hao F, Liu XM, Sun QN, Wang Y, Lai W, Fang H, Tu YT, Sun Q, Chen J, Gao XH, Gu Y, Teixeira HD, Zhang JZ, Okun MM. Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol Venereol. 2017 Jan 31(1). 89-95. 2.Cai L, Zhang JZ, Yao X, Gu J, Liu QZ, Zheng M, Zhang SF, Xu JH, Li CX, Cheng H, Guo Q, Pan WL, Li SQ, Li RY, Guo ZP, Song ZQ, Li SS, Dong XQ, Wang L, Fu R, Regnault P, Charef P, Mazur R, Patekar M. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis.Chinese Medical Journal 2020;133(22):2665-73. 3.Cai L, Chen GH, Lu QJ, Zheng M, Li YZ, Chen J, Zheng J, Zhang FR, Yu JB, Yang S, Li FQ, Xiao SX, Sun QN, Xu JH, Gao XH, Fang H, Gao TW, Hao F, Liu QZ, Tu YT, Li RY, Wang BX, Deng DQ, Zheng QS, Liu HX, Zhang JZ. A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis. Chin Med J 2020; 133(24):2905-2909. 4.Cai L, Zhang JZ, Zheng M, Zhang SF, Patekar M. Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis.. Chin Med J 2021; 134(21):2629-2631. 5.Cai L. Li LF. Cheng H. Ding YF. Biao ZS. Zhang SF. Geng SM. Liu QZ. Fang H. Song ZQ. Lu Y. Li SS. Guo Q. Tao J. He L. Gu J. Yang QP. Han XP. Gao XH. Deng DQ. Li SQ. Wang QY. Zhu J. Zhang JZ. Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study. Adv Ther; 2022 Jan.39(1):583-597. 6.Zhao Z, Cai L, Zhang S, Zhang H, Liu XY, Li CL, Zhao Y, Zhang JZ. Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis. Original Article Chin Med J 2022; 135(12) 1438-1443.(IF: 6.133 ). 7.Zhang S, Cai L, Zhang H, Zhao Z, Liu XY, Zhao Y, Zhang JZ. Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis. Chin Med J 2022; 135(18)2248-2250. (IF: 6.133 ). 8.Liu Xiaoyang, Zhao Yan,Mu Zhanglei,Jia Yuan,Liu Chen, Zhang Jianzhong,Cai Lin.The Combination of IL-6, PLR and Nail Psoriasis: Screen for the Early Diagnosis of Psoriatic Arthritis. Clinical, Cosmetic and Investigational Dermatology 2023:16 1703–1713 (ASP); 、; 、;;; 、..: 1.Cai L, Gu J, Zheng J, Zheng M, Wang G, Xi LY, Hao F, Liu XM, Sun QN, Wang Y, Lai W, Fang H, Tu YT, Sun Q, Chen J, Gao XH, Gu Y, Teixeira HD, Zhang JZ, Okun MM. Efficacy and safety of adalimumab in Chinese patients with moderate-to-severe plaque psoriasis: results from a phase 3, randomized, placebo-controlled, double-blind study. J Eur Acad Dermatol Venereol. 2017 Jan 31(1). 89-95. 2.Cai L, Zhang JZ, Yao X, Gu J, Liu QZ, Zheng M, Zhang SF, Xu JH, Li CX, Cheng H, Guo Q, Pan WL, Li SQ, Li RY, Guo ZP, Song ZQ, Li SS, Dong XQ, Wang L, Fu R, Regnault P, Charef P, Mazur R, Patekar M. Secukinumab demonstrates high efficacy and a favorable safety profile over 52 weeks in Chinese patients with moderate to severe plaque psoriasis.Chinese Medical Journal 2020;133(22):2665-73. 3.Cai L, Chen GH, Lu QJ, Zheng M, Li YZ, Chen J, Zheng J, Zhang FR, Yu JB, Yang S, Li FQ, Xiao SX, Sun QN, Xu JH, Gao XH, Fang H, Gao TW, Hao F, Liu QZ, Tu YT, Li RY, Wang BX, Deng DQ, Zheng QS, Liu HX, Zhang JZ. A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis. Chin Med J 2020; 133(24):2905-2909. 4.Cai L, Zhang JZ, Zheng M, Zhang SF, Patekar M. Efficacy and safety of secukinumab over 52 weeks in Chinese psoriasis patients with concomitant psoriatic arthritis.. Chin Med J 2021; 134(21):2629-2631. 5.Cai L. Li LF. Cheng H. Ding YF. Biao ZS. Zhang SF. Geng SM. Liu QZ. Fang H. Song ZQ. Lu Y. Li SS. Guo Q. Tao J. He L. Gu J. Yang QP. Han XP. Gao XH. Deng DQ. Li SQ. Wang QY. Zhu J. Zhang JZ. Efficacy and Safety of HLX03, an Adalimumab Biosimilar, in Patients with Moderate-to-Severe Plaque Psoriasis: A Randomized, Double-Blind, Phase III Study. Adv Ther; 2022 Jan.39(1):583-597. 6.Zhao Z, Cai L, Zhang S, Zhang H, Liu XY, Li CL, Zhao Y, Zhang JZ. Effects of secukinumab and adalimumab on serum uric acid level in patients with plaque psoriasis. Original Article Chin Med J 2022; 135(12) 1438-1443.(IF: 6.133 ). 7.Zhang S, Cai L, Zhang H, Zhao Z, Liu XY, Zhao Y, Zhang JZ. Effects of adalimumab and secukinumab on comorbidities associated with metabolism in patients with plaque psoriasis. Chin Med J 2022; 135(18)2248-2250. (IF: 6.133 ). 8.Liu Xiaoyang, Zhao Yan,Mu Zhanglei,Jia Yuan,Liu Chen, Zhang Jianzhong,Cai Lin.The Combination of IL-6, PLR and Nail Psoriasis: Screen for the Early Diagnosis of Psoriatic Arthritis. Clinical, Cosmetic and Investigational Dermatology 2023:16 1703–1713 、 | | | |:: 11:100044 ICP: ICP 10005257 -1 COPYRIGHT © 2004-2026:88326666: APP